A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.
The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback